Marker Therapeutics, Inc. (MRKR)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue TTM

0 2.5M 5M 7.5M Q4 '17: 183.1K Q1 '18: 183.1K Q2 '18: 389.1K Q3 '18: 206K Q4 '18: 206K Q1 '19: 206K Q2 '19: 0 Q3 '19: 0 Q4 '19: 213.2K Q1 '20: 246.4K Q2 '20: 713.2K Q3 '20: 713.2K Q4 '20: 500K Q4 '22: 3.5M Q1 '23: 3.8M Q2 '23: 3.8M Q3 '23: 3M Q4 '23: 3.3M Q1 '24: 3.3M Q2 '24: 3.7M Q3 '24: 5.4M Q4 '24: 6.6M Q1 '25: 5.7M Q2 '25: 5.4M Q3 '25: 4.7M Q4 '25: 3.5M Q1 '26: 3.9M Q2 '18 Q2 '19 Q2 '20 Q1 '23 Q1 '24 Q1 '25 Q1 '26

Gross Profit TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Income TTM

-180M -120M -60M 0 60M 120M 180M Q3 '16: -9.2M Q4 '16: -8.5M Q1 '17: -9.2M Q2 '17: -9.1M Q3 '17: -10.4M Q4 '17: -11.5M Q1 '18: -12.3M Q2 '18: -14.5M Q3 '18: -15M Q4 '18: -148.2M Q1 '19: -150.6M Q2 '19: -151.8M Q3 '19: -153M Q4 '19: -22.5M Q1 '20: -23.5M Q2 '20: -24M Q3 '20: -25.7M Q4 '20: -28.9M Q1 '21: -31M Q2 '21: -35.6M Q3 '21: -38.2M Q4 '21: -39.5M Q1 '22: -40.5M Q2 '22: -34.9M Q3 '22: -30.7M Q4 '22: -23.9M Q1 '23: -18.4M Q2 '23: -17.3M Q3 '23: -14.7M Q4 '23: -14.6M Q1 '24: -12.8M Q2 '24: -11M Q3 '24: -10.2M Q4 '24: -11.1M Q1 '25: -13.5M Q2 '25: -16.3M Q3 '25: -16.1M Q4 '25: -14.1M Q1 '26: -13.2M Q2 '26: -10.7M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Net Income TTM

-180M -120M -60M 0 60M 120M 180M Q3 '16: -2.5M Q4 '16: -2.5M Q1 '17: -125.5K Q2 '17: -8M Q3 '17: -9.9M Q4 '17: -11M Q1 '18: -11.8M Q2 '18: -14.7M Q3 '18: -15.1M Q4 '18: -148M Q1 '19: -150.1M Q2 '19: -150.8M Q3 '19: -151.9M Q4 '19: -21.4M Q1 '20: -22.6M Q2 '20: -23.4M Q3 '20: -25.3M Q4 '20: -28.7M Q1 '21: -31M Q2 '21: -35.6M Q3 '21: -40.6M Q4 '21: -41.9M Q1 '22: -43M Q2 '22: -41.3M Q3 '22: -35.8M Q4 '22: -29.9M Q1 '23: -25M Q2 '23: -13.2M Q3 '23: -9.3M Q4 '23: -8.2M Q1 '24: -5.7M Q2 '24: -10.4M Q3 '24: -9.7M Q4 '24: -10.7M Q1 '25: -12.8M Q2 '25: -14.6M Q3 '25: -14.3M Q4 '25: -12.2M Q1 '26: -10.9M Q2 '26: -8.7M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Cost of Revenue TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Cash Flow TTM

-45M -30M -15M 0 15M 30M 45M Q3 '16: -5.6M Q4 '16: -6.5M Q1 '17: -7.6M Q2 '17: -7.7M Q3 '17: -7.7M Q4 '17: -8.4M Q1 '18: -8.9M Q2 '18: -9.2M Q3 '18: -10.8M Q4 '18: -14.5M Q1 '19: -16M Q2 '19: -17.8M Q3 '19: -19.9M Q4 '19: -18.3M Q1 '20: -18.5M Q2 '20: -18.6M Q3 '20: -19.1M Q4 '20: -20M Q1 '21: -24M Q2 '21: -26.5M Q3 '21: -27.9M Q4 '21: -27.3M Q1 '22: -31.4M Q2 '22: -25.4M Q3 '22: -25.5M Q4 '22: -27M Q1 '23: -20.6M Q2 '23: -26.9M Q3 '23: -20.4M Q4 '23: -16.4M Q1 '24: -14.4M Q2 '24: -10.9M Q3 '24: -8.6M Q4 '24: -10.9M Q1 '25: -12.6M Q2 '25: -10.9M Q3 '25: -14.8M Q4 '25: -12M Q1 '26: -7.9M Q2 '26: -9.8M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Free Cash Flow TTM

-21M -14M -7M 0 7M 14M 21M Q2 '12: -988.2K Q3 '12: -1.1M Q4 '18: -14.6M Q1 '19: -16.4M Q2 '19: -18.2M Q3 '19: -20.4M Q4 '19: -18.7M Q1 '20: -18.8M Q2 '12 Q3 '12 Q4 '18 Q1 '19 Q2 '19 Q3 '19 Q4 '19 Q1 '20

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 30M 60M 90M Q3 '11: 47.2M Q3 '12: 73.1M Q3 '14: 17.3M Q2 '15: 33.5M Q3 '15: 6.7M Q2 '16: 6.5M Q3 '16: 7.3M Q1 '17: 8.4M Q2 '17: 8.6M Q3 '17: 10.2M Q1 '18: 10.6M Q2 '18: 11.8M Q3 '18: 13.7M Q1 '19: 45.5M Q2 '19: 45.5M Q3 '19: 45.7M Q1 '20: 46.1M Q2 '20: 46.6M Q3 '20: 46.9M Q1 '21: 56.5M Q2 '21: 83M Q3 '21: 83.1M Q1 '22: 8.3M Q2 '22: 8.4M Q3 '22: 8.4M Q1 '23: 8.7M Q2 '23: 8.8M Q3 '23: 8.8M Q1 '24: 8.9M Q2 '24: 8.9M Q3 '24: 8.9M Q1 '25: 11.1M Q2 '25: 14M Q3 '25: 16.8M Q1 '26: 19.3M Q2 '26: 19.3M Q3 '11 Q2 '16 Q1 '18 Q3 '19 Q2 '21 Q1 '23 Q3 '24 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-9.00 -6.00 -3.00 0.00 3.00 6.00 9.00 Q3 '14: -6.80 Q4 '16: -0.93 Q1 '17: -0.41 Q2 '17: -0.98 Q3 '17: -1.08 Q4 '17: -1.15 Q1 '18: -1.16 Q2 '18: -1.35 Q3 '18: -1.28 Q4 '18: -7.75 Q1 '19: -7.57 Q2 '19: -7.28 Q3 '19: -7.08 Q4 '19: -0.47 Q1 '20: -0.49 Q2 '20: -0.51 Q3 '20: -0.55 Q4 '20: -0.62 Q1 '21: -0.64 Q2 '21: -0.63 Q3 '21: -0.62 Q4 '21: -5.48 Q1 '22: -6.51 Q2 '22: -7.49 Q3 '22: -8.17 Q4 '22: -3.58 Q1 '23: -2.96 Q2 '23: -1.56 Q3 '23: -1.07 Q4 '23: -0.94 Q1 '24: -0.64 Q2 '24: -1.18 Q3 '24: -1.10 Q4 '24: -1.20 Q1 '25: -1.33 Q2 '25: -1.37 Q3 '25: -1.23 Q4 '25: -0.85 Q1 '26: -0.61 Q2 '26: -0.41 Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.